Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1159/000444990 http://scihub22266oqcxt.onion/10.1159/000444990 C4926886!4926886!27413730     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Visc+Med 2016 ; 32 (2): 121-6 Nephropedia Template TP {{tp|p=27413730|t=2016. Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and Prognosis |pdf=|usr=}}{{27413730}} gab.com Text Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and Prognosis JO: Visc Med http://www.kidney.de/pget.php?&tw=1&pmid=27413730 #FOAvip Background: Chronic hepatitis B and C infections represent major risk factors for the development of hepatocellular carcinoma (HCC). Recently, the management of patients with viral hepatitis has dramatically changed. In the present review we discuss the impact of these developments on the prevention of HCC as well as the treatment of patients with HCC. Methods: Studies indexed in Medline between 1990 and 2015 (November) were reviewed. The terms ?hepatocellular carcinoma?, ?HCC?, ?hepatitis B?, ?hepatitis C?, ?viral hepatitis?, and combinations of these terms were used. Results: Patients with chronic hepatitis B or hepatitis C without HCC should be evaluated for antiviral therapy, since antiviral therapy was suggested to reduce the risk of HCC development. Cirrhotic patients infected with hepatitis B virus (HBV) require antiviral therapy, while cirrhotics infected with hepatitis C virus (HCV) need to be prioritized for therapy with interferon (IFN)-free regimens. Antiviral therapy should be considered in HBV-infected patients with HCC, especially to prevent tumor recurrence after curative-intended therapy or to prevent hepatic decompensation. HCV-infected patients with HCC should be considered in similar intention for IFN-free antiviral therapy, depending on the tumor stage and life expectancy. Conclusion: Patients with viral hepatitis should be considered for antiviral treatment for the prevention of HCC development as well as during HCC treatment. Twit Text FOAVip Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and Prognosis ????Visc Med http://www.kidney.de/pget.php?&tw=1&pmid=27413730 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27413730 #FOAvip English Wikipedia <ref>{{Cite pmid|27413730}}</ref> Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and Prognosis #MMPMID27413730 Roderburg C; Tacke F; Trautwein C Visc Med 2016[Apr]; 32 (2): 121-6 PMID27413730show ga Background: Chronic hepatitis B and C infections represent major risk factors for the development of hepatocellular carcinoma (HCC). Recently, the management of patients with viral hepatitis has dramatically changed. In the present review we discuss the impact of these developments on the prevention of HCC as well as the treatment of patients with HCC. Methods: Studies indexed in Medline between 1990 and 2015 (November) were reviewed. The terms ?hepatocellular carcinoma?, ?HCC?, ?hepatitis B?, ?hepatitis C?, ?viral hepatitis?, and combinations of these terms were used. Results: Patients with chronic hepatitis B or hepatitis C without HCC should be evaluated for antiviral therapy, since antiviral therapy was suggested to reduce the risk of HCC development. Cirrhotic patients infected with hepatitis B virus (HBV) require antiviral therapy, while cirrhotics infected with hepatitis C virus (HCV) need to be prioritized for therapy with interferon (IFN)-free regimens. Antiviral therapy should be considered in HBV-infected patients with HCC, especially to prevent tumor recurrence after curative-intended therapy or to prevent hepatic decompensation. HCV-infected patients with HCC should be considered in similar intention for IFN-free antiviral therapy, depending on the tumor stage and life expectancy. Conclusion: Patients with viral hepatitis should be considered for antiviral treatment for the prevention of HCC development as well as during HCC treatment. äAntiviral Therapy in Patients with Viral Hepatitis and Hepatocellular (epmc).pdf DeepDyve Pubget Overpricing